ClinicaliQ Trial Snapshot
- A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD — Recruiting • Phase III • Gastroenterology • NCT06847542.
- Trial testing a surgically implanted eye device that delivers ranibizumab every 36 weeks for age-related macular degeneration.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD. Conditions: Neovascular Age-related Macular Degeneration Interventions: Susvimo PDS Implant, Ranibizumab Lead Sponsor: Hoffmann-La Roche Planned Enrollment: 250 participants